SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-073843
Filing Date
2020-06-17
Accepted
2020-06-16 17:38:05
Documents
7
Period of Report
2020-06-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2022704d1_8k.htm 8-K 22802
2 EXHIBIT 1.1 tm2022704d1_ex1-1.htm EX-1.1 268575
3 EXHIBIT 5.1 tm2022704d1_ex5-1.htm EX-5.1 9484
4 EXHIBIT 99.1 tm2022704d1_ex99-1.htm EX-99.1 9962
5 EXHIBIT 99.2 tm2022704d1_ex99-2.htm EX-99.2 10543
6 GRAPHIC tm2022704d1_ex99-1img001.jpg GRAPHIC 10623
7 GRAPHIC tm2022704d1_ex99-2img001.jpg GRAPHIC 7910
  Complete submission text file 0001104659-20-073843.txt   348607
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-15006 | Film No.: 20967435
SIC: 2835 In Vitro & In Vivo Diagnostic Substances